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Abstract: Atherosclerosis is a chronic cardiovascular disease which increases risk of major
cardiovascular events including myocardial infarction and stroke. Elevated plasma concentrations of
asymmetric dimethylarginine (ADMA) have long been recognised as a hallmark of cardiovascular
disease and are associated with cardiovascular risk factors including hypertension, obesity and
hypertriglyceridemia. In this review, we discuss the clinical literature that link ADMA concentrations
to increased risk of the development of atherosclerosis. The formation of atherosclerotic lesions
relies on the interplay between vascular dysfunction, leading to endothelial activation and the
accumulation of inflammatory cells, particularly macrophages, within the vessel wall. Here, we
review the mechanisms through which elevated ADMA contributes to endothelial dysfunction,
activation and reactive oxygen species (ROS) production; how ADMA may affect vascular smooth
muscle phenotype; and finally whether ADMA plays a regulatory role in the inflammatory processes
occurring within the vessel wall.
Keywords: asymmetric dimethylarginine; atherosclerosis; dimethylarginine dimethylaminohydrolase;
endothelial dysfunction; plaque formation
1. Introduction and Overview
In 1992, Vallance et al. were the first to observe that asymmetric dimethylarginine (ADMA)
was elevated in chronic kidney disease patients [1]. Nearly 30 years on, raised ADMA is recognised
as a hallmark of endothelial dysfunction [2], and, as such, related to many cardiovascular risk
factors hypertension [3], obesity [4,5], hypertriglyceridemia [6] and type 1 [7] and type 2 diabetes [8].
In addition, longitudinal studies reveal that ADMA predicts cardiovascular morbidity and mortality in
both myocardial infarction (MI) [9] and stroke patients [10]. Crucially, these studies have demonstrated
that ADMA-driven cardiovascular risk is conserved, even when traditional and non-traditional risk
factors are controlled. This review intends to explore the association between plasma ADMA and
atherosclerosis, and to identify the potential causal mechanisms underlying ADMA’s role in the
vascular and inflammatory processes involved in plaque formation.
The methylation of arginine residues is one of a myriad of post-translational modifications. ADMA,
along with symmetric dimethylarginine (SDMA) and NG-mono-methylated-L-arginine (L-NMMA),
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is produced by protein arginine methyltransferase (PRMT) enzymes [11]. Nine PRMT enzymes have
been identified to date, with all of them capable of forming mono-methylated-L-arginine. Type 1
PRMTs, of which PRMT1 is the most promiscuous, include PRMTs 3, 4 (also known as CARM1),
6 and 8, which catalyse the production of ADMA. In contrast, type 2 PRMTs, of which PRMT5 is the
best described, are responsible for the formation of SDMA. In all cases, however, there are currently
no known demethylation steps for arginine and, as such, ‘free’ methylarginines are released into
the cytosol following proteolysis and can be transported into the circulation by cationic amino acid
transporters [12]. ADMA and L-NMMA have been of interest to vascular scientists since they were
shown to be endogenous inhibitors of nitric oxide synthase (NOS) via competition with L-arginine,
the requisite NOS substrate and structural analogue of ADMA and L-NMMA [1,13]. In healthy serum,
the concentration of ADMA is between 0.4 and 0.6 µM [14]; in contrast, the serum concentration
of L-NMMA is 5–10 fold lower at ~0.05 µM [15]. The third methylarginine SDMA is found at
concentrations similar to that of ADMA [14]. Although not discussed further in this review, SDMA has
also been identified as an independent cardiovascular risk factor and predictor of all-cause mortality.
Albeit that SDMA is not a direct inhibitor of NOS, SDMA can still alter L-arginine concentrations via
competition at amino acid transporters. However, the biological relevance of this and further unknown
mechanisms still needs to be investigated to fully understand how SDMA affects clinical outcome [15].
Arginine methylation is a constitutive process and, as such, free ADMA concentrations would
quickly become elevated if not regulated, with resultant physiological consequences. In human
volunteers, a pathophysiological bolus dose of ADMA significantly increased blood pressure [16] and
inhibited forearm flow-mediated dilatation [17], consistent with inhibition of NOS. Renal excretion
accounts for approximately 20% of the elimination of endogenous ADMA, with plasma ADMA
elevated in renal failure patients [1,18,19]. The primary route of elimination involves the metabolism of
ADMA by dimethylarginine dimethylaminohydrolase 1 and 2 (DDAH1 and DDAH2) to citrulline and
dimethylamine. Given the importance of DDAH in ADMA clearance, several in vivo studies have been
undertaken to understand whether DDAH dysfunction plays a causal role in cardiovascular disease.
Work by our group and others has shown that both heterozygous and homozygous DDAH1
deficiency, via the disruption of either exon 1 or 4, increased serum ADMA and ADMA
accumulation in tissues. These findings were associated with a broad derangement of cardiovascular
function, including elevated blood pressure, increased systemic vascular resistance and impaired
vasoreactivity [20–22]. Conversely, overexpression of DDAH1 via viral transfection and genetic
strategies lead to reduced ADMA levels with a corresponding decrease in blood pressure [23,24].
Interestingly, global deletion of DDAH2, through targeted disruption of exon 2, did not alter plasma
ADMA but did lead to increased urinary, myocardial and renal ADMA accumulation with a resultant
fall in plasma total nitrate and nitrite (NOx) concentrations [25]. This was associated with decreased
endothelial-dependent relaxation and increased vasoconstriction, with systemic blood pressure raised
during periods of activity. Overexpression of DDAH2 decreased accumulation of ADMA but had no
influence on blood pressure [26]. Subsequent examination of DDAH2-/- mice has revealed that ADMA
accumulation occurs in the retina following oxygen-induced retinopathy and that this was associated
with improved revascularisation [27]. Therefore, evidence suggests that while ADMA can promote
vascular dysfunction in many settings, ADMA may also mediate protective effects in the vasculature
due to its role in inflammatory cells. Finally, a third enzyme, alanine-glyoxylate aminotransferase-2
(AGXT2), accounts for a limited amount of ADMA metabolism. As with DDAH, we found AGXT2
deletion led to elevated ADMA and higher blood pressure [28]. Together, these in vivo observations
support the notion that altered ADMA concentrations and metabolism have a causal role in the
development of vascular derangement.
2. Clinical Association of ADMA with Atherosclerosis
The association between elevated plasma ADMA and the traditional risk factors for atherosclerosis
has led to numerous clinical studies to determine whether ADMA is an independent factor in the
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development of atherosclerosis itself. Hypercholesteremia is a known driver of plaque formation,
providing the low-density lipoprotein (LDL) cholesterol that forms the basis of the fatty lesion [29].
ADMA concentrations have been correlated with plasma LDL [30], and a lower L-arginine/ADMA
ratio detected in hypercholesteraemic subjects [31].
Carotid artery intima–media thickness (IMT) is often used as a marker of atherosclerotic
development in otherwise healthy individuals. Multiple studies have demonstrated a strong
relation between increased IMT and elevated ADMA independent of other risk factors in healthy
volunteers [32,33]. Flow-mediated dilatation (FMD) of the brachial artery, a common site of
atherosclerosis, is also strongly associated with carotid artery IMT [34]. In a cohort of aged participants,
FMD was negatively associated with the L-arginine/ADMA ratio. However, no association was
observed with ADMA [35]. In contrast, analysis of the Young Finns study found that elevated plasma
ADMA concentrations were associated with reduced FMD. Although male sex was a significant
predictor of ADMA, there was no significant sex difference on the association between ADMA and
FMD [36].
Interestingly, a number of prospective studies have also demonstrated that high ADMA is
predictive of coronary artery disease (CAD). Furuki et al. determined that there was a significant
relationship between baseline ADMA concentrations and IMT after a 6 year follow up in a healthy
Japanese population [37]. There are suggestions that ADMA may exhibit site-specific promotion of
subclinical atherosclerosis, as demonstrated by the Framingham Offspring Cohort Study which found
ADMA concentrations were not linked with common carotid artery thickness but were found to affect
the carotid bulb and internal carotid artery [38]. The Shimane CoHRE cross-sectional study, however,
found no association between IMT with either ADMA or L-arginine concentration alone, whilst a
decreased L-arginine/ADMA ratio did associate with IMT, thus suggesting that the L-arginine/ADMA
ratio may be a more sensitive marker for atherosclerosis [39].
The importance of the ADMA-metabolizing enzymes, DDAH and AGXT2, has also been confirmed in
clinical studies of CAD. Plasma ADMA levels are influenced by genetic variation in both DDAH1 [40–42]
and DDAH2 [40,43]. In Chinese populations, a DDAH1 polymorphism, the promotor variant -396 4N,
confers an increased risk of stroke, thrombosis and CAD [41]. Smaller cohort studies which have
demonstrated a positive association between ADMA accumulation and DDAH1 genotype have been
linked to hypertension [44] and CAD [42]. Interestingly, recent work in CAD patients has indicated
that CAD incidence and ADMA levels are increased by AGXT2 variants rs37369 and rs16899974 [42].
In contrast to the above studies, Zsuga et al. found a negative relationship between ADMA and
IMT, suggesting a protective effect of ADMA in inflammatory conditions characterized by increased
iNOS [45]. They suggest that the extent of ADMA elevation is key in determining whether iNOS or
eNOS blockade occurs in the disease process.
Meta-analyses agree there is substantial variation in the effect of ADMA. However, Xuan et al.
still concluded that overall ADMA concentrations are significantly increased in CAD patients [46].
Upon further analysis, this correlation remained in patients with either MI or angina pectoris but there
was no such relationship in those with acute coronary syndrome or slow coronary flow. Bai et al.
again concluded that high plasma ADMA levels were associated with carotid IMT, with this link being
stronger in subjects with chronic kidney disease [47].
In patients with CAD, ADMA was found to be an independent predictor of mortality in patients
admitted with MI [48] and to have prognostic value beyond traditional risk factors in predicting further
cardiovascular events [49]. Similarly, the Population Study of Women in Gothenburg revealed that
systemic ADMA levels predicted the likelihood of both myocardial infarction and stroke over a 24 year
period [9]. Furthermore, a meta-analysis by Willeit et al. observed a positive correlation between
ADMA and risk of stroke [50]. Together, these human studies show a strong association between
elevated ADMA concentrations on the development of CAD and contribute to worse outcome with
increased likelihood of MI. However, these human studies cannot determine whether ADMA has a
causal role in the pathogenesis of atherosclerosis.
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3. Underlying Mechanisms of Atherosclerosis
It is well understood that atherosclerosis is both a vascular and inflammatory disease and
this has been reviewed extensively [51,52]. However, to outline where ADMA may play a
mechanistic role, atherosclerotic lesion formation and development will be briefly described here.
In normal physiology, shear stress caused by high laminar blood flow protects the endothelium
by suppressing proinflammatory factors and enhancing the release of vasoactive mediators such
as NO, which as well as regulating vascular tone have anti-proliferative and anti-thrombotic effects.
Lesions, in contrast, tend to occur in areas subjected to low shear stress and disturbed flow such as
arterial branch points and areas of high vessel curvature. These areas exhibit increased permeability,
allowing macromolecules including oxidised LDL (oxLDL) to migrate into the subendothelial space [53].
The atherogenic modifications of migrated LDL particles mark them as proinflammatory, inducing
inflammatory endothelial signalling pathways including nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-kB). Consequently, the expression of NF-kB-dependent genes are upregulated
including adhesion molecules, cytokines and growth factors. Macrophages migrate into the vessel
wall and actively ingest and accumulate oxLDL, converting to foam cells [29]. Smooth muscle cells
proliferate, producing large quantities of extracellular matrix, forming a fibrous cap over what can
become a necrotic core [54]. Stable lesions can limit blood flow, causing local ischemia. However, upon
plaque rupture, a thrombotic state occurs, which can in turn trigger the catastrophic events of a MI or
cerebral stroke.
Early animal models of atherosclerosis using a hypercholesterolemic diet documented high plasma
levels of ADMA and endothelial dysfunction in both rabbits [55] and monkeys [56]. In addition, plasma
ADMA is raised in genetic [57] and pharmacological murine models of atherosclerosis [26]. In wild-type
C57BL/6J mice, exogenous ADMA treatment triggers the development of aortic lesions [58] and induces
perivascular fibrosis and intimal thickening in the coronary microvasculature [59]. Treatment of
proatherogenic apolipoprotein E-deficient (ApoE-/-) mice with exogenous ADMA also exacerbates
aortic lesion burden [58]. To study the significance of DDAH1 in atherosclerosis pathogenesis,
Jacobi et al. developed a DDAH1-overexpressing, ApoE-/- mouse model. Compared to ApoE-/-
counterparts, ADMA was lowered in DDAH1-overexpressing mice, which resulted in improved
endothelial relaxation, decreased aortic lesion burden, as well as reduced neointimal lesion area
and CD68 macrophage staining in the brachiocephalic trunk [57]. Consistently, Hasegawa et al.
showed that angiotensin-II (Ang-II)-induced intimal thickening and perivascular fibrosis of coronary
microvasculature is prevented by DDAH2 overexpression [26]. Interestingly, DDAH1 overexpression
in femoral artery injury models improves endothelial repair, suppresses neointima formation and
reduces local CD45 leukocyte infiltration [60], suggesting that elevated plasma ADMA levels might
impact on atherogenesis by inhibiting vascular repair processes. These findings implicate ADMA as a
culprit molecule in the development of atherosclerosis.
3.1. Endothelial Activation
Endothelial activation is typified by reduced endothelial barrier function, enhanced expression of
adhesion molecules and an altered secretory profile, which impacts inflammation, homeostasis, cell
behaviour and vascular tone [61]. Given the association between ADMA and endothelial dysfunction,
several studies have attempted to elucidate the mechanisms through which ADMA may affect
atherosclerotic lesion formation.
The role of ADMA in endothelial barrier function has been explored by several studies,
in vitro [62–65] and in vivo [62]. ADMA treatment of porcine pulmonary artery endothelial cells (ECs)
increased FITC-dextran permeability and actin stress fiber formation, which could be normalised by
overexpression of DDAH and attenuated by the protein kinase G (PKG) activator 8-Bromo-cGMP or
adenoviral mediated ras-related C3 botulinum toxin substrate 1 (Rac1) overexpression. This effect
was also evident in DDAH1-/- pulmonary microvascular cells, where basal levels of permeability
were increased. Importantly, the effect of DDAH1 deletion was conserved in vivo, where reduced
J. Clin. Med. 2020, 9, 3026 5 of 17
pulmonary endothelial barrier function resulted in increased Evans Blue accumulation in the
lung [62,66]. Wang et al. later showed that ADMA enhanced apelin-13 passage through an endothelial
monolayer in a concentration- and time-dependent manner, leading to increased myosin light chain
phosphorylation in cocultured vascular smooth muscle cells (vSMCs) [64]. ADMA treatment again
led to actin re-organisation and a dispersal of adherens junctions which were ameliorated by both
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase inhibitor apocynin and the p38
mitogen activated protein kinase (MAPK) inhibitor SB203580, indicating that ADMA may influence
EC permeability by mediating actin cytoskeleton organisation through reactive oxygen species (ROS)
and p38 MAPK signalling. These findings suggest that an ADMA-mediated reduction in endothelial
barrier integrity could contribute to oxLDL accumulation in atherosclerosis although this is still to be
definitively investigated.
Under resting conditions, endothelial cell adhesion molecule expression and chemokine secretion
is largely inhibited, keeping endothelial and circulating immune cell interaction to a minimum.
Following inflammatory stimulation, ECs transition to an activated state, where they secrete a range
of proinflammatory and chemotactic molecules, particularly monocyte chemoattractant protein-1
(MCP-1), Interleukin 6 (IL-6) and 8 (IL-8) [52]. Expression of P- and E-selectins and Ig-superfamily
molecules intracellular adhesion molecule 1 (ICAM1) and vascular cell adhesion protein 1 (VCAM1),
which mediate endothelial-leukocyte interactions and leukocyte transmigration into the subintimal
space, are enhanced [67]. In human vascular disease, elevated ADMA is correlated with increased
circulating levels of ICAM-1 [68] and VCAM-1 [69] and has been linked with increased circulating
C-reactive protein (CRP), a prominent marker of EC activation [68,70]. These human studies have
led to speculation that ADMA may influence EC activation and hence mediate proinflammatory
actions in the endothelium (Figure 1). In vitro, ADMA treatment induced endothelial expression of
ICAM-1 [63,71], VCAM-1 [72], the oxLDL receptor LOX-1 [73] as well as the proinflammatory cytokines
MCP-1 [74] and tumour necrosis factor (TNF)-α [75]. Chan et al. demonstrated a functional effect
where not only did ADMA dose-dependently enhance monocytoid cell adhesion to ECs in vitro but
that plasma the L-arginine/ADMA ratio correlates inversely with peripheral blood mononuclear cell
adhesion in hypercholestremic patients [30].
NF-κB is a key transcription factor in proinflammatory endothelial activation. Targeted endothelial
inhibition of NF-κB signalling in ApoE-/- mice reduced macrophage recruitment and decreased lesion
area [76]. Consistently, ADMA has been shown to activate NF-κB in ECs [71,72,74,75]. Guo et al.
demonstrated that ADMA increased nuclear translocation of NF-κB, which coincided with increased
ICAM-1 expression in HUVECs. This was again associated with actin stress fiber formation and
abolished following actin modulation by jasplakinolide and cytochalasin D [71]. Subsequent work
by the group revealed that ADMA increased the degradation of NF-κB’s inhibitory partner, nuclear
factor of kappa-light-chain polypeptide gene enhancer of B- cells inhibitor (IκBα), and facilitated
NF-κB p65 subunit/actin interaction. Actin fiber disruption had no effect on ADMA-mediated
IκBα degradation, but both NF-κB translocation and NF-κB p65/actin association were impaired,
ameliorating ADMA-mediated NF-κB activation and VCAM-1 expression [72]. These observations
would suggest that the proinflammatory actions of ADMA in the endothelium are dependent on actin
cytoskeleton modulation. Other studies report that ADMA-induced NF-κB activation and soluble
ICAM-1 expression is concomitantly linked with p38 MAPK and extracellular signal related kinases
(ERK) 1/2 phosphorylation [75]. Interestingly, inhibition of p38 MAPK and ERK1/2 attenuated the
effect of ADMA on both ICAM expression and NF-κB activation. Accordingly, ADMA-induced NF-κB
activation appears to be regulated upstream by p38 MAPK and ERK1/2 signalling. Given the central
role of NF-κB, its modulation by ADMA could be a significant mechanistic link through which ADMA
impacts the endothelial inflammatory state. It will be interesting to determine whether ADMA affects
other NF-κB downstream targets such as cyclooxygenase-2 and matrix metalloproteinase expression
and assess their role in endothelial activation.
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Figure 1. Asymmetric dimethylarginine increases endothelial activation. At the site of atherosclerotic 
lesions, inflammation leads to endothelial activation, reducing endothelial barrier integrity, 
enhancing the expression of adhesion molecules and increasing endothelial production of 
inflammatory markers. Asymmetric dimethylarginine (ADMA) treatment of endothelial cell 
monolayers increased endothelial permeability, increasing oxLDL transmigration. Actin cytoskeleton 
remodelling and reactive oxygen species (ROS) production, which are both induced by ADMA 
treatment, lead to the upregulation of ERK and NF-kB signalling and increased cytokine production. 
ADMA treatment also increases the expression of adhesion molecules ICAM and VCAM, leading to 
increased monocyte adhesiveness. Abbreviations: ADMA—asymmetric dimethylarginine, oxLDL—
oxidised low-density lipoprotein, ROS—reactive oxygen species, ERK—extracellular signal related 
kinase, NF-kB—nuclear factor kappa-light-chain enhancer of activated B cells, ICAM—intracellular 
adhesion molecule, VCAM—vascular cell adhesion protein, MCP-1—monocyte chemoattractant 
protein 1, TNF α—tumour necrosis factor alpha, IL8—interleukin 8. 
Scalera et al. demonstrated that ADMA treatment of human umbilical vein endothelial cells 
(HUVECs) reduced telomerase activity, enhanced telomere attrition and decreased β-galactosidase 
activation, consistent with cellular aging and senescence [77]. In addition, ADMA-induced 
senescence was linked with MCP-1 and IL-8 expression and was sensitive to pyrrolidine 
dithiocarbamate antioxidant treatment. Given that NF-κB is an established mediator of ROS-
dependent MCP-1 and IL-8 expression, Scalera et al. postulated that ADMA-induced senescence is 
ROS dependent, and that again NF-κB signalling may be implicated. EC senescence is enhanced in 
atherosclerotic lesions and is associated with a reduction in eNOS activity in vitro [78]. Taken 
together, these data suggest that ADMA may mediate atherogenesis through reduced endothelial 
barrier function, altered NF-κB signalling and actin fiber re-organisation, accelerating EC senescence 
and promoting endothelial inflammation and dysfunction. 
3.2. Oxidative Stress in Endothelial Cells 
As briefly mentioned above, the overproduction of reactive oxygen species (ROS) is a feature of 
many cardiovascular pathologies. In the coronary vasculature, enhanced oxidative burden is an 
important hallmark of atherosclerosis progression and lesion instability [79], with systemic levels of 
ROS predicting cardiovascular events in CAD [80]. ADMA accumulation, endothelial dysfunction 
and oxidative stress have been independently linked to CAD [81]. ADMA and ROS both disrupt NO 
signalling, suggesting that they may interact to cause, or reinforce, vascular impairment and disease 
[81,82]. Antoniades et al. demonstrated that high serum ADMA correlates with enhanced superoxide 
production in both saphenous veins and internal mammary arteries derived from CAD patients [83]. 
However, to date, the association between ADMA and vascular ROS levels in CAD has not been 
extensively examined in a clinical setting. 
The protective effects of vascular NO can, in part, be attributed to ROS scavenging and activation 
of endogenous antioxidant defense systems which act to mitigate effects of vascular ROS 
accumulation [84]. Thus, by reducing NO bioavailability, ADMA may promote vascular ROS 
Figure 1. Asymmetric dimethylarginine increases endothelial activation. At the site of atherosclerotic
lesions, inflammation leads to endothelial activation, reducing endothelial barrier integrity, e hancing
the expression of adhesion molecules and increasing endothelial production of inflammatory markers.
Asy etric di ethylarginine (ADMA) treatment of endothelial cell monolayers increased endothelial
permeability, increasing oxLDL trans igration. Actin cytoskeleton remodelling and reactive oxygen
species (ROS) production, which are both induced by ADMA treatment, lead to the upregulation of ERK
and NF-kB signalling and increased cytokine production. ADMA treatment also increases the expression
of adhesion molecules ICAM and VCAM, leading to increased monocyte adhesiveness. Abbreviations:
ADMA—asymmetric dimethylarginine, oxLDL—oxidised low-density lipoprotein, ROS—reactive
oxygen species, ERK—extracellular signal related kinase, NF-kB—nuclear factor kappa-light-chain
enhancer of activated B cells, ICAM—intracellular adhesion molecule, VCAM—vascular cell adhesion
protein, MCP-1—monocyte chemoattractant protein 1, TNF α—tumour necrosis factor alpha,
IL8—interleukin 8.
Scalera et al. demonstrated that ADMA treatment of human umbilical vein endothelial cells
(HUVECs) reduced telomerase activity, enhanced telomere attrition and decreased β-galactosidase
activation, consistent with cellular aging and senescence [77]. In addition, ADMA-induced senescence
was linked with MCP-1 and IL-8 expression and was sensitive to pyrrolidine dithiocarbamate
antioxidant treatment. Given that NF-κB is an established mediator of ROS-dependent MCP-1 and
IL-8 expression, Scalera et al. postulated that ADMA-induced senescence is ROS dependent, and that
again NF-κB signalling may be implicated. EC senescence is enhanced in atherosclerotic lesions
and is associated with a reduction in eNOS activity in vitro [78]. Taken together, these data suggest
that ADMA may mediate atherogenesis through reduced endothelial barrier function, altered NF-κB
signalling and actin fiber re-organisation, accelerating EC senescence and promoting endothelial
inflammation and dysfunction.
3.2. Oxidative Stress in Endothelial Cells
As briefly mentioned above, the overproduction of reactive oxygen species (ROS) is a feature
of many cardiovascular pathologies. In the coronary vasculature, enhanced oxidative burden is an
important hallmark of atherosclerosis progression and lesion instability [79], with systemic levels of
ROS predicting cardiovascular events in CAD [80]. ADMA accumulation, endothelial dysfunction
and oxidative stress have been independently linked to CAD [81]. ADMA and ROS both disrupt
NO signalling, suggesting that they may interact to cause, or reinforce, vascular impairment and
disease [81,82]. Antoniades et al. demonstrated that high serum ADMA correlates with enhanced
superoxide production in both saphenous veins and internal mammary arteries derived from CAD
patients [83]. However, to date, the association between ADMA and vascular ROS levels in CAD has
not been extensively examined in a clinical setting.
The protective effects of vascular NO can, in part, be attributed to ROS scavenging and activation of
endogenous antioxidant defense systems which act to mitigate effects of vascular ROS accumulation [84].
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Thus, by reducing NO bioavailability, ADMA may promote vascular ROS imbalance contributing
to endothelial dysfunction. However, ADMA is also thought to invoke superoxide production via
eNOS uncoupling. Treatment of HUVECs with 1 mM ADMA increased superoxide formation by
~130% [83], while 10 µM ADMA caused a ~2-fold increase in production [74]. Böger et al. reported
that ADMA-driven endothelial superoxide generation was accompanied by NF-κB activation and
secretion of the chemotactic protein MCP-1 [74]. Suda et al. have shown that long-term ADMA
treatment stimulated cardiac superoxide production, which was related to increased coronary artery
lesion formation in mice [59]. Interestingly, lesion formation in eNOS-deficient mice was comparable to
wild types, suggesting that ADMA can modulate oxidative burden via NO-independent mechanisms.
ADMA may also inhibit antioxidant defence systems. In rats, chronic ADMA administration reduces
systemic activity of superoxide dismutase (SOD), glutathione peroxidiase and catalase. Crucially,
this was accompanied by increased circulating levels of the lipid peroxidation and oxidative stress
marker malondialdehyde [85]. Accordingly, ADMA not only contributes to ROS burden through
multiple mechanisms, but may also reduce ROS disposal, therein establishing a pathogenic redox
state in the vasculature. ADMA signalling itself may also be regulated by ROS; in rat gracilis muscle
arterioles, ADMA concentration-dependent contraction was abolished by the presence of SOD [86].
Veresh et al. later demonstrated that the effect of ADMA on basal tone and flow-mediated dilatation
was prevented by both endothelial denudation and the NADPH inhibitor apocynin, implicating
superoxide generation and endothelial function as requisite mediators in the vascular response to
ADMA [87]. Together, these findings indicate a causal role for ADMA in establishing oxidative stress
driven vascular damage. However, whether ADMA can invoke ROS-mediated endothelial dysfunction
at pathologically relevant concentrations seen in atherosclerosis is still unclear.
Of note, while ADMA potentially acts to induce vascular oxidation, studies in vitro show
that DDAH activity may be reduced under conditions of nitrosative [88] and oxidative stress [89].
Furthermore, oxLDL caused a reduction in endothelial DDAH1 activity, which coincided with ADMA
formation [90]. Conversely, PRMT expression and ADMA levels in ECs are positively regulated by
oxLDL [91]. This would suggest that ADMA levels are likely to be increased in response to enhanced
ROS signalling. In the context of endothelial dysfunction, positive feedback loops involving ROS
elaboration and its reciprocal interactions with proatherogenic factors such as oxLDL play a role in
sustaining EC activation and amplifying atherosclerosis advancement [92]. It could be speculated that
ROS regulation of enzymatic mediators of ADMA metabolism, in concert with ADMA-driven ROS
production, may also be an important pathogenic mechanism in vascular disease.
3.3. Plaque Formation
The proliferation of smooth muscle cells drives the formation of a fibrous cap under which
inflammatory cells accumulate and eventually form a necrotic core [54]. Lesions with a large fibrous
cap are thought to be stable and, although these can cause local ischemia, are protective against
thrombotic events. In contrast, a thin smooth muscle layer promotes instability, with rupture triggering
a thrombotic cascade, which can lead to major cardiovascular events including MI and stroke. Most
clinical studies associating ADMA plasma concentrations with atherosclerotic development use
markers of neointima hyperplasia or vessel calcification [32,33,37,38]. However, although EC-produced
NO is a key regulator of vSMC function, there have been relatively few studies to determine whether
ADMA has mechanism effects in smooth muscle proliferation, extracellular matrix deposition or
plaque calcification.
Interestingly, although NOS is not expressed in vSMCs under basal conditions, DDAH is expressed
constitutively. DDAH1 expression has been demonstrated by gene expression and Western blotting [93,94],
while DDAH2 has been identified in both myofibrils and in smooth muscle nuclei [95]. This suggests
that DDAH may be an important regulator of vSMC iNOS activity or be important for the metabolism of
ADMA produced elsewhere. Endothelial-produced ADMA has been shown to act as a soluble signalling
molecule on vSMCs, increasing their proliferation through the induction of ERK signalling [96].
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Furthermore, in a model of pulmonary arterial hypertension, ADMA treatment has been shown to
upregulate vSMC proliferation, likely through an upregulation of Rho kinase signalling [97]. Rho A
and Rho kinase (ROCK) signalling has again been implicated in the ADMA-mediated increase in vSMC
migration. ADMA treatment led to the increased phosphorylation of ROCK downstream target MYPT-1,
which led to the reorganisation of the actin cytoskeleton and altered vSMC morphology. Treatment with
the ROCK inhibitor Y27632 and overexpression of DDAH2 both reverse the ADMA-driven increase in
vSMC migration [98].
The proinflammatory cytokines chemokine (c-c motif) ligand 5 (CCL5) and IL-1β are both thought
to contribute to neointimal hyperplasia. Surprisingly, however, treatment of vSMCs with either cytokine
increased DDAH1 expression, leading to suppression of ADMA accumulation and amplification
of iNOS signalling [93,94]. Neither of these studies look beyond the effect on DDAH to determine
how reducing ADMA effected vSMC proliferation. The conflicting evidence on the effect of ADMA
on vSMC proliferation and migration suggests that further work in the setting of atherosclerosis is
needed to determine how the interaction between ADMA signalling and inflammation regulates
vSMC phenotype.
Stenting is a common treatment for CAD and, following stent placement, plasma ADMA
concentrations fall, with a corresponding increase in arginine concentration, leading to a significant
improvement in the arginine/ADMA ratio. This suggests that either the plaque itself or the associated
ischemic condition is a factor contributing to raised ADMA concentration [99]. However, following
stenting, ADMA is a determining factor as to whether re-stenosis occurs, with ADMA concentrations
correlating with in-stent calcification and neoatherosclerosis [100]. Stenting can cause endothelial
damage. Therefore, high ADMA concentrations can block endothelial re-growth, leading to neointimal
growth. Konishi et al. found that DDAH1 overexpression rescued this phenotype, resulting in lower
levels of proliferation and inflammatory cell infiltration [60]. These studies suggest that ADMA
concentrations are key to successful treatment of atheromas, and methods to lower ADMA would be
beneficial to improved outcomes of angioplasty patients.
3.4. Inflammation
Atherosclerosis is accompanied by chronic, low-grade inflammation, where oxidised LDL particles
in the vessel wall lead to the recruitment of inflammatory cells to the lesion [29]. As discussed above,
the activation of NF-kB in the endothelium promotes the expression of selectins and adhesion markers,
which in turn trigger the transmigration of immune cells [52,67]. Although inflammatory mechanisms
of atherosclerosis have been extensively reviewed [51], here we discuss how ADMA modulates this
immune response.
Following migration to the lesion, monocytes differentiate into the proinflammatory M1
macrophage. Classically activated M1 macrophages release a variety of proinflammatory cytokines,
chemokines and reactive oxygen species which contribute to the maintenance of the local inflammatory
response [51]. The expression of iNOS and NO production are also hallmarks of M1 macrophages,
contributing to tissue damage; given the status of ADMA as a NO inhibitor, its involvement in
macrophage iNOS signalling is of interest. Early studies by Macallister et al. demonstrated that ADMA
inhibited NO production in cultured human and murine macrophages in a concentration-dependent
manner [101]. Similarly, a more recent study demonstrated ADMA as a regulator of LPS-induced
NO production in macrophages via inhibition of NF-kB activity and consequent suppression of
iNOS mRNA and protein expression [102]. ADMA also enhanced the formation of superoxide in
macrophages in vivo, identifying a negative correlation between an ADMA-dependent decrease in
NO production and an ADMA-dependent increase in superoxide release [102]. In inflammatory
cells, ADMA metabolism is confined to DDAH2 and, we have, therefore, investigated the impact of
DDAH2 deficiency on macrophage function [25,103]. As expected, ADMA concentration was notably
higher in DDAH2-/- peritoneal macrophages, with a corresponding reduction in NOx production
following treatment with a polyfactorial proinflammatory treatment consisting of interferon-γ, LPS and
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TNFα. We demonstrated impaired stimulated macrophage phagocytic activity and motility in cells
from both global and monocyte-specific DDAH2-/- mice. Such findings indicate the ability of ADMA
and impaired ADMA metabolism to negatively influence the balance in the production of reactive
mediators during inflammatory states. However, whether ADMA alters NO production in models of
atherosclerosis has not been investigated.
At the site of the lesion, differentiated macrophages express a high level of scavenger receptors
including the lectin-like, oxidized, lipoprotein receptor (LOX-1). Scavenger receptors, including LOX1,
play a crucial role in early atherogenesis and are involved in LDL uptake and subsequent generation
of foam cells. Smirnova et al. found that treatment of PMA-primed human monocytic leukaemia
cells with ADMA significantly increased the expression of LOX-1 by 217% (Figure 2). This increase
was coupled with a more than 2-fold upregulation of oxLDL accumulation [104]. Following uptake,
oxLDL is degraded by lysosomes, generating free cholesterol to be trafficked to the endoplasmic
reticulum and esterified by Acyl-coenzyme A: cholesterol acyltransferase (ACAT). In THP-1-derived
macrophages and foam cells, ADMA treatment increased the expression of ACAT-1, leading to
increasing cellular cholesterol content in a time- and concentration-dependent manner [105]. Since LDL
cholesterol upregulates the generation of ADMA [91] and ADMA increases oxLDL uptake, it would
suggest a positive feedback loop, where ADMA concentrations drive foam cell formation within the
atherosclerotic plaque.
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The ATP-binding cassette (ABC) transporters ABCA1 and ABCG1 are regulated by the nuclear
liver x receptor (LXR) which is activated by cholesterol metabolites. When macrophage function is
impaired, their ability to effectively efflux cholesterol is reduced, contributing to foam cell formation.
Interestingly, a recent study proposed that ADMA treatment of macrophages reduced liver X receptor
alpha (LXRα) activity, downregulating the expression of ABCA1 and ABCG1 transporters via the
activation of NADPH oxidase ROS generation. As a result, cholesterol efflux was impaired, and ADMA
drove excessive macrophage lipid accumulation [106]. Overexpression of DDAH2 was protective
and returned cholesterol efflux to normal levels. Failure of proper clearance of lipids can lead to
macrophage apoptosis, contributing to the development of a necrotic core. ADMA treatment of
THP-1 cells induced ER stress and increased caspase 4 activity, eventually leading to higher levels of
apoptosis [107]. Together, these data suggest that while ADMA may suppress inflammatory processes
via iNOS inhibition, ADMA also promotes foam cell formation, a key driver in plaque development.
Therefore, the balance of these processes needs to be fully understood in vivo to determine whether
the regulation of ADMA metabolism in innate immune cells is a viable target for the treatment
of atherosclerosis.
While lipid-laden macrophages are the predominant immune cell type within an atherosclerotic
plaque, there are also a significant number of T cells found within the lesion. It is now clear that the
adaptive immune response plays a significant role in the development and progression of atherosclerosis.
It has been suggested that differing subsets of T cells play opposing roles in atherogenesis although
compensatory mechanisms have left much still to be determined [108]. Unlike the extensive literature
relating to the impact of ADMA/NO signalling in macrophages, very little is known about this pathway
in T cells and this is still a field of research for future study.
Recent advances in the treatment of CAD have focused on chronic inflammation playing an active
role in the development of atherogenic disease. A number of trials, including COLCOT and CANTOS,
have shown that intervening in IL-1β or IL6 signalling pathways is successful in improving patient
outcome [109,110]. A number of clinical studies have shown a positive association between high
concentrations of IL-6 and ADMA in patients with CAD and those undergoing angioplasty [111,112];
similar associations have also been demonstrated in rheumatoid arthritis [111] and septic shock [113].
However, as with all studies which show association, there is no mechanistic insight as to the
relationship between interleukin signalling and ADMA concentration and it would be of future interest
to understand whether ADMA/NO signalling was affected in the major inflammatory trials.
4. Conclusions
Although there have been major advances in the treatment of atherosclerotic plaques, their
frequency within the population contributes to the high rates of catastrophic cardiovascular events
including MI and stroke. Furthermore, although angioplasty and stenting have been a breakthrough
in the management of lesions, they do not always maintain longevity due to neointima formation
and restenosis. As a result, understanding the mechanisms which underly plaque formation is key to
the development of new treatments. Elevated plasma ADMA not only correlates with the presence
of plaques, particularly in the carotid artery, but also predicts risk of future lesion development,
myocardial infarction and stroke. It is, therefore, important to determine the mechanisms underlying
ADMA-related risk. In vivo and in vitro studies clearly demonstrate that exogenous ADMA and
impaired ADMA metabolism have a profound effect on endothelial function, reducing barrier integrity
while increasing inflammatory markers and ROS production. Many of these effects are through the
inhibition of NO production, although the dependence on NO is not clear in all studies. The role of
ADMA in inflammatory cells, however, is not as clear. Proatherogenic pathways via foam cell formation
would again suggest that ADMA plays a key role in lesion formation. However, a number of studies
have indicated that ADMA can be beneficial in controlling chronic inflammatory pathways via the
suppression of iNOS signalling. Given that inflammatory cells are unique in only expressing DDAH2,
this may make this an interesting target in controlling the inflammatory processes in established disease.
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